PCSK9 inhibition to reduce cardiovascular disease risk: Recent findings from the biology of PCSK9

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 22, Issue 2, 2015, Pages 126-132

  Tavori, Hagai ^a   Giunzioni, Ilaria ^a   Fazio, Sergio ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

LDL cholesterol; LDL receptor; lipoprotein(a); PCSK9 inhibition; triglycerides

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; EVOLOCUMAB; HUMAN MONOCLONAL ANTIBODY; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; LDLR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR;

BIOLOGY; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFICACY; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL SOCIETY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PRACTICE GUIDELINE; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; ANIMAL; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; DRUG EFFECTS; DYSLIPIDEMIAS; ENZYMOLOGY; IMMUNOLOGY; LIPID METABOLISM; METABOLISM; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; PROPROTEIN CONVERTASES; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84926375797     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000137     Document Type: Review

References (80)

1. Hunt KJ, Resendez RG, Williams K, et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 2004; 110:1251-1257.
2. Ellison RC, Zhang Y, Wagenknecht LE, et al. Relation of the metabolic syndrome to calcified atherosclerotic plaque in the coronary arteries and aorta. Am J Cardiol 2005; 95:1180-1186.
3. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 1997; 278:313-321.
4. Christopher P Cannon on behalf of the IMPROVE IT Investigators1 CD, Brigham and Womens Hosp. Boston MA. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndrome. Circulation 2014; 130:2105-2126.
5. Stone NJ, Robinson GJ, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation published online November 12, 2013.
6. Avis HJ, Hutten BA, Gagne C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol 2010; 55:1121-1126.
7. Rallidis LS, Fountoulaki K, Anastasiou-Nana M. Managing the underestimated risk of statin-associated myopathy. Int J Cardiol 2012; 159:169-176.
8. Bays H, Cohen DE, Chalasani N, Harrison SA. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol 2014; 8 (3 Suppl):S47- 57.
9. Brault M, Ray J, Gomez YH, et al. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 2014; 63:735-745.
10. Park SW, Moon YA, Horton JD. Posttranscriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J Biol Chem 2004; 279:50630-50638.
11. Benjannet S, Rhainds D, Essalmani R, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004; 279:48865-48875.
12. Cohen J, Pertsemlidis A, Kotowski IK, et al. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005; 37:161-165.
13. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterollowering effects ofAMG145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408-2417.
14. Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891-1900.
15. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the PCSK9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia. Circulation 2013; 128:2113-2120.
16. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet 2014; 383:60-68.
17. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370:1809-1819.
18. Raal FJ, Giugliano RP, Sabatine MS, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1, 300 patients in 4 phase II trials. J Am Coll Cardiol 2014; 63:1278-1288.
19. Gaudet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014; 114:711-715.
20. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380:2007-2017.
21. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-1118.
22. Dubuc G, Tremblay M, Pare G, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res 2010; 51:140-149.
23. Seidah NG, Prat A. The proprotein convertases are potential targets in the treatment of dyslipidemia. J Mol Med 2007; 85:685-696.
24. Ai D, Chen C, Han S, et al. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice. J Clin Invest 2012; 122:1262-1270.
25. Jeong HJ, Lee HS, Kim KS, et al. Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res 2008; 49:399-409.
26. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem 2006; 281:6211-6218.
27. Mayne J, Dewpura T, Raymond A, et al. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis 2008; 7:22.
28. Careskey HE, Davis RA, Alborn WE, et al. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res 2008; 49:394-398.
29. Welder G, Zineh I, Pacanowski MA, et al. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res 2010; 51:2714-2721.
30. Davignon J, Dubuc G. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc 2009; 120:163-173.
31. Seidah NG, Sadr MS, Chretien M, Mbikay M. The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions. J Biol Chem 2013; 288:21473-21481.
32. Chorba JS, Shokat KM. The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. J Biol Chem 2014; 289:29030-29043.
33. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem 2007; 282:20799-20803.
34. Zhang DW, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007; 282:18602-18612.
35. Lipari MT, Li W, Moran P, et al. Furin-cleaved proprotein convertase subtilisin/ kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levels. J Biol Chem 2012; 287:43482-43491.
36. Benjannet S, Rhainds D, Hamelin J, et al. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and posttranslational modifications. J Biol Chem 2006; 281:30561-30572.
37. Han B, Eacho PI, Knierman MD, et al. Isolation and characterization of the circulating truncated form of PCSK9. J Lipid Res 2014; 55:1505-1514.
38. Fan D, Yancey PG, Qiu S, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry 2008; 47:1631-1639.
39. Kosenko T, Golder M, Leblond G, et al. Low-density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in human plasma and inhibits PCSK9-mediated LDL receptor degradation. J Biol Chem 2013; 288:8279-8288.
40. Tavori H, Giunzioni I, Linton MF, Fazio S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res 2013; 113:1290-1295.
41. Tavori H, Fan D, Blakemore JL, et al. Serum proprotein convertase subtilisin/ kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013; 127:2403-2413.
42. Yamamoto T, Lu C, Ryan RO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem 2011; 286:5464-5470.
43. Zhang DW, Garuti R, Fau-Tang W-J, et al. Structural requirements for PCSK9- mediated degradation of the low-density lipoprotein receptor. Proc Natl Acad Sci U S A 2008; 105:13045-13050.
44. Desai NR, Kohli P, Giugliano RP, et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial. Circulation 2013; 128:962-969.
45. Stein EA, Giugliano RP, Koren MJ, et al. Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014; 35:2249-2259.
46. Desai NR, Giugliano RP, Zhou J, et al. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57). J Am Coll Cardiol 2014; 63:430-433.
47. Robinson JG, Nedergaard BS, Rogers WJ, et al. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. J Am Med Assoc 2014; 311:1870-1882.
48. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370:1809-1819.
49. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 2014; 63:2531-2540.
50. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:341-350.
51. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int J Cardiol 2014; 176:55-61.
52. Postmus I, Trompet S, de Craen AJ, et al. PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J Lipid Res 2013; 54:561-566.
53. Goldstein JL, Brown MS. Regulation of low-density lipoprotein receptors: implications for pathogenesis and therapy of hypercholesterolemia and atherosclerosis. Circulation 1987; 76:504-507.
54. Fazio S, Linton MF, Hasty AH, Swift LL. Recycling of apolipoprotein E in mouse liver. J Biol Chem 1999; 274:8247-8253.
55. Farkas MH, Swift LL, Hasty AH, et al. The recycling of apolipoprotein E in primary cultures of mouse hepatocytes. Evidence for a physiologic connection to high density lipoprotein metabolism. J Biol Chem 2003; 278:9412-9417.
56. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006; 79:514-523.
57. Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 2012; 125:894-901.
58. Sasaki M, Terao Y, Ayaori M, et al. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways. Arterioscler Thromb Vasc Biol 2014; 34:1171-1178.
59. Raal F, Panz V, Immelman A, Pilcher G. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013; 2:e000028.
60. Guardamagna O, Restagno G, Rolfo E, et al. The type of LDLR gene mutation predicts cardiovascular risk in children with familial hypercholesterolemia. J Pediatr 2009; 155:199-204. (e2).
61. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, et al., editors. The metabolic and molecular bases of inherited disease, 8th ed McGraw-Hill; 2001. pp. 2863-2913.
62. Stein EA, Honarpour N, Wasserman SM, et al. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013; 128:2113-2120.
63. Gao F, Ihn HE, Medina MW, Krauss RM. A common polymorphism in the LDL receptor gene has multiple effects on LDL receptor function. Hum Mol Genet 2012; 22:1424-1431.
64. Somanathan S, Jacobs F, Wang Q, et al. AAV vectors expressing LDLR gainof- function variants demonstrate increased efficacy in mouse models of familial hypercholesterolemia. Circ Res 2014; 115:591-599.
65. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Metaanalysis of prospective studies. Circulation 2000; 102:1082-1085.
66. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
67. Gaubatz JW, Heideman C, Gotto AM Jr, et al. Human plasma lipoprotein [a]. Structural properties. J Biol Chem 1983; 258:4582-4589.
68. van Dijk RA, Kolodgie F, Ravandi A, et al. Differential expression of oxidationspecific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012; 53:2773-2790.
69. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012; 126:2283-2292.
70. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Genetic, epidemiologic and clinical data strongly suggest that fasting or nonfasting triglycerides are independent cardiovascular risk factors. Curr Med Res Opin 2014; doi:10.1185/03007995.2014.958147. [Epub ahead of print]
71. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of nonfasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9:258-270.
72. TG and HDL Working Group of the Exome Sequencing Project, National Heart Lung and Blood Institute. Crosby J, Peloso GM, Auer PL, et al. Loss-offunction mutations in APOC3, triglycerides, and coronary disease. N Engl J MedicineV 371 2014; 22-31.
73. Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjaerg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371:32-41.
74. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385:331-340.
75. Levy E, Ben Djoudi Ouadda A, Spahis S, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 2013; 227:297-306.
76. Rashid S, Tavori H, Brown P, et al. PCSK9 promotes intestinal overproductin of triglyceride-rich apolipoprotien-B liporptoein through both LDL-receptor dependent and independent mechanisms. Circulation 2014; 130:431-441.
77. Rashid S, Curtis DE, Garuti R, et al. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc Natl Acad Sci U S A 2005; 102:5374-5379.
78. Le May C, Kourimate S, Langhi C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol 2009; 29:684-690.
79. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89:331-340.
80. Poirier S, Mayer G, Benjannet S, et al. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem 2008; 283:2363-2372.